8 out of a 100 vs. 13 out of a 100. NICE will see right through that. Even if they believe it they'll say $300,000 a piece for 87 out of 100 who won't see any real benefit. Perhaps they'll allow for some small identifiable subset but that won't help shareholders.
>>what you fail to say is it's roughly a 50% increase in the numbers that make it to 5 years.
10% increase of 50 out of a hundred is a lot better than 10% of 8 out of 100.
>>The FDA has often approved drugs that permit 10% of the patients to live longer, we're talking 50% living longer and many others who lived less than 5 years still living longer than with SOC treatment.
I'm not ignoring it but NICE will. It's an old trial not powered for OS. Sounds like it could be a promising combo that requires a real Pll.
>>Of course you completely ignore that adding Poly-ICLC or other therapeutics should move that 5% to over 50%, but only if used with DCVax-L. I grant the evidence is only from a small trial, but it's none the less very definitive.
It'll take years of coordination before Eden ever shows any costs savings. And, even if NICE authorizes payment for a small subset, Eden will be pretty much useless.
>>Approval will mean nothing if the vaccine can't be produced in the needed commercial quantities, so I also believe it won't be that long before the EDEN Unit is approved so that sort of production is possible without years of constructing and certifying tiny clean rooms for manual production of the vaccine.
News 
Market Data 
Discover 
